vimarsana.com

Latest Breaking News On - Viking therapeutics daily - Page 1 : vimarsana.com

Viking Therapeutics, Inc (NASDAQ:VKTX) Receives $112 38 Average Target Price from Brokerages

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average […]

Viking Therapeutics, Inc (NASDAQ:VKTX) Receives $112 38 Average Price Target from Analysts

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year […]

Viking Therapeutics (NASDAQ:VKTX) Upgraded at StockNews com

StockNews.com upgraded shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) to a sell rating in a research report report published on Friday. Other research analysts have also issued reports about the stock. William Blair reissued an outperform rating on shares of Viking Therapeutics in a report on Friday, February 23rd. HC Wainwright restated a buy […]

Viking Therapeutics (VKTX) Buy Rating Reaffirmed at Truist Financial

Truist Financial reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $120.00 price objective on the biotechnology company’s stock. A number of other analysts have also recently weighed in on VKTX. BTIG Research increased their price objective on […]

Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from Truist Financial

Truist Financial reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $120.00 target price on the biotechnology company’s stock. A number of other equities analysts have also weighed in on the stock. StockNews.com upgraded […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.